Find out more about who we are, what we do and the people behind Epitopea.
Find out what makes us unique and the work we do with our revolutionary CryptoMapTM platform.
All the latest company news, press releases and updates from Epitopea.
Contact

News & Events:

Revealing the true targets for next generation immunotherapies.
Learn More

Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic

Date: July 10, 2025 |
CAMBRIDGE, UK and MONTREAL, CANADA, 10 July 2025 – Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, […]
Read More

Epitopea Announces Nature Cancer Paper on Novel Immunotherapy Targets in Melanoma and NSCLC

Date: May 27, 2025 |
Further Validates CryptigensTM as Actionable Targets for Cancer Immunotherapy Montreal, Quebec, & Cambridge, UK, 27 May 2025 – Epitopea, a […]
Read More

Epitopea Featured in BiotechTV

Date: May 9, 2025 |
Cambridge, UK based Epitopia is helping Merck (MSD) discover tumor associated antigens from the non-coding regions of the genome using […]
Read More

Epitopea Featured in Fierce Biotech

Date: February 19, 2025 |
Merck pens $300M-per-product collab with Epitopea to locate 'hidden' tumor antigens Merck & Co. has penned a $300 million biobucks-per-product […]
Read More

Epitopea Announces License and Research Collaboration Agreement with MSD to Identify CryptigenTM Tumor-Specific Antigens

Date: February 19, 2025 |
Montreal, Quebec and Cambridge, UK February 19, 2025: Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, announces […]
Read More

Epitopea Appoints Klaus Edvardsen M.D., Ph.D. as Chief Medical Officer 

Date: February 7, 2025 |
CAMBRIDGE, UK and MONTREAL, CANADA, 7 February 2025 — Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies, […]
Read More

Epitopea and Genevant Sciences Announce Collaboration Agreement

Date: December 19, 2024 |
CAMBRIDGE, UK, MONTREAL, CANADA, VANCOUVER, CANADA, and BASEL, SWITZERLAND — December 19, 2024 (GLOBE NEWSWIRE) — Epitopea, a transatlantic cancer […]
Read More

Epitopea Featured in Cambridge Independent

Date: November 4, 2024 |
Epitopea’s $31m pre-Series A is boost for RNA immunotherapies clinical trials Epitopea’s transatlantic business model has been boosted by a […]
Read More

CQDM and Epitopea Fund the Development and Validation of CryptoMapTM a Platform Enabling the Development of RNA-based Immunotherapies

Date: September 26, 2024 |
Montreal, Quebec, 26 September 2024 – Epitopea, a transatlantic cancer immunotherapy company, and CQDM are proud to announce the launch […]
Read More

Epitopea Awarded Grant from Innovate UK’s Cancer Therapeutics Programme

Date: September 12, 2024 |
Grant to advance development of Cryptigen immunotherapeutics for cancer CAMBRIDGE, UK and MONTREAL, CANADA, 12 September 2024 - Epitopea, a […]
Read More
1 2
Revealing Novel Targets For Next Generation Immunotherapies
© 2022 – 2025 Epitopea Ltd | All Rights Reserved
Created by FDM Digital